EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Treatment Strategy for Rifampin-Susceptible Tuberculosis

Nicholas I Paton iD, Christopher Cousins, Celina Suresh, Erlina Burhan, Ka Lip Chew, Victoria B Dalay, Qingshu Lu, Tutik Kusmiati, Vincent M Balanag, Shu Ling Lee, Rovina Ruslami, Yogesh Pokharkar und 10 weitere

New England Journal of Medicine · 09.03.2023 · 388 (10) · 873-887

DOI: 10.1056/nejmoa2212537 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.03.2023. Verfasst von Nicholas I Paton und 21 weiteren Autor:innen. Beteiligte Einrichtung: From the Infectious Diseases Translational Research Programme and Yong Loo Lin School of Medicine, National University of Singapore (N.I.P., C.C., C.…. Hauptthemen laut MEDLINE: Antitubercular Agents, Linezolid, Rifampin, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 139-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Wellcome Trust, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tuberculosis is usually treated with a 6-month rifampin-based regimen. Whether a strategy involving shorter initial treatment may lead to similar outcomes is unclear. METHODS: In this adaptive, open-label, noninferiority trial, we randomly assigned participants with rifampin-susceptible pulmonary tuberculosis to undergo either standard treatment (rifampin and isoniazid for 24 weeks with pyrazinamide and ethambutol for the first 8 weeks) or a strategy involving initial treatment with an 8-week regimen, extended treatment for persistent clinical disease, monitoring after treatment, and retreatment for relapse. There were four strategy groups with different initial regimens; noninferiority was assessed in the two strategy groups with complete enrollment, which had initial regimens of high-dose rifampin-linezolid and bedaquiline-linezolid (each with isoniazid, pyrazinamide, and ethambutol). The primary outcome was a composite of death, ongoing treatment, or active disease at week 96. The noninferiority margin was 12 percentage points. RESULTS: Of the 674 participants in the intention-to-treat population, 4 (0.6%) withdrew consent or were lost to follow-up. A primary-outcome event occurred in 7 of the 181 participants (3.9%) in the standard-treatment group, as compared with 21 of the 184 participants (11.4%) in the strategy group with an initial rifampin-linezolid regimen (adjusted difference, 7.4 percentage points; 97.5% confidence interval [CI], 1.7 to 13.2; noninferiority not met) and 11 of the 189 participants (5.8%) in the strategy group with an initial bedaquiline-linezolid regimen (adjusted difference, 0.8 percentage points; 97.5% CI, -3.4 to 5.1; noninferiority met). The mean total duration of treatment was 180 days in the standard-treatment group, 106 days in the rifampin-linezolid strategy group, and 85 days in the bedaquiline-linezolid strategy group. The incidences of grade 3 or 4 adverse events and serious adverse events were similar in the three groups. CONCLUSIONS: A strategy involving initial treatment with an 8-week bedaquiline-linezolid regimen was noninferior to standard treatment for tuberculosis with respect to clinical outcomes. The strategy was associated with a shorter total duration of treatment and with no evident safety concerns. (Funded by the Singapore National Medical Research Council and others; TRUNCATE-TB ClinicalTrials.gov number, NCT03474198.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsLinezolidRifampinTuberculosis, PulmonaryDiarylquinolinesHumansDrug Administration ScheduleDrug Therapy, CombinationEthambutolIsoniazidPyrazinamideTreatment OutcomeTuberculosis, Multidrug-Resistant

Substanzen

Antitubercular AgentsEthambutolIsoniazidLinezolidPyrazinamideRifampinbedaquilineDiarylquinolines

Autor:innen und Institutionen

  • From the Infectious Diseases Translational Research Programme and Yong Loo Lin School of Medicine, National University of Singapore (N.I.P., C.C., C.S., P.P.), National University Hospital (K.L.C.), and Singapore Clinic…

ORCID-Profile: Nicholas I Paton, Padmasayee Papineni

Förderung

  • Medical Research Council
  • Wellcome Trust
  • National Medical Research Council

Zitieren

APA

Paton, N. I., Cousins, C., Suresh, C., Burhan, E., Chew, K. L., Dalay, V. B., Lu, Q., Kusmiati, T., Balanag, V. M., Lee, S. L., Ruslami, R., Pokharkar, Y., Djaharuddin, I., Sugiri, J. J. R., Veto, R. S., Sekaggya-Wiltshire, C., Avihingsanon, A., Sarin, R., Papineni, P., …, & TRUNCATE-TB Trial Team (2023). Treatment Strategy for Rifampin-Susceptible Tuberculosis. New England Journal of Medicine, 388(10), 873-887. https://doi.org/10.1056/nejmoa2212537

Vancouver

Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, et al. Treatment Strategy for Rifampin-Susceptible Tuberculosis. New England Journal of Medicine. 2023;388(10):873-887. doi:10.1056/nejmoa2212537

BibTeX
@article{Paton2023,
  author = {Paton, Nicholas I and Cousins, Christopher and Suresh, Celina and Burhan, Erlina and Chew, Ka Lip and Dalay, Victoria B and Lu, Qingshu and Kusmiati, Tutik and Balanag, Vincent M and Lee, Shu Ling and Ruslami, Rovina and Pokharkar, Yogesh and Djaharuddin, Irawaty and Sugiri, Jani J R and Veto, Rholine S and Sekaggya-Wiltshire, Christine and Avihingsanon, Anchalee and Sarin, Rohit and Papineni, Padmasayee and Nunn, Andrew J and Crook, Angela M and TRUNCATE-TB Trial Team, TRUNCATE-TB Trial Team},
  title = {Treatment Strategy for Rifampin-Susceptible Tuberculosis},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {10},
  pages = {873--887},
  doi = {10.1056/nejmoa2212537}
}
Kostenlos starten →